Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients with Advanced Breast and Gastrointestinal Tumors
Conditions
Gastrointestinal Tumors | Metastatic Breast Cancer
What is the purpose of this trial?
The purpose of this study is to find the maximum and optimally tolerated dose of the combination of two drugs. The two drugs are Sorafenib and Capecitabine. The drug Sorafenib is an approved drug which is used to treat certain cancers. The drug Capecitabine is approved to treat patients with advanced breast cancer as well as early stage colon cancer. However, the combination of Sorafenib and Capecitabine is not FDA approved.Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Bayer Pharmaceuticals
Yale Cancer Center - Dates:
- July 2012
- Last Updated:
- Study HIC#:
- 1112009424
Clinicaltrials.gov ID: Yale0051494
